{"groups":[{"description":"Participants receive BMS-986213 (IV fixed-dose combination relatlimab/nivolumab at a 1:3 ratio) every 4 weeks (Q4W).\n\nFor adults, dosing is relatlimab 160 mg/nivolumab 480 mg. Adolescents ≥ 40 kg will receive adult dosing; for adolescents \\< 40 kg, dosing is relatlimab 2 mg/kg/nivolumab 6 mg/kg.","id":"FG000","title":"Arm A: Relatlimab + Nivolumab"},{"description":"Participants receive Nivolumab IV monotherapy every 4 weeks (Q4W).\n\nDosing for adults is 480 mg. Adolescents ≥ 40 kg will receive adult dosing; for adolescents \\< 40 kg, dosing is 6 mg/kg.","id":"FG001","title":"Arm B: Nivolumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"107"},{"groupId":"FG001","numSubjects":"118"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"9"}],"type":"Participant Withdrew Consent"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Other reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Not reported"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"355"},{"groupId":"FG001","numSubjects":"359"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"237"},{"groupId":"FG001","numSubjects":"227"}],"comment":"Continuing in the study","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"118"},{"groupId":"FG001","numSubjects":"132"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"714 Participants were randomized and received study treatment"}